Protexa Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Protexa Therapeutics General Information

Description

Developer of proprietary pharmaceutical products based on a platform of TGF-beta production stimulators. The company's lead product is a proprietary fixed-dose combination of droloxifene and clopidogrel, being developed for the treatment of cardiovascular disease, and in particular acute coronary syndromes.

Contact Information

Formerly Known As
Johns Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 9 St Johns Street
  • Cambridgeshire
  • Duxford CB22 4RA
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 9 St Johns Street
  • Cambridgeshire
  • Duxford CB22 4RA
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Protexa Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Jan-2012 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Protexa Therapeutics’s complete valuation and funding history, request access »

Protexa Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Total Medical Ventures Venture Capital Minority
To view Protexa Therapeutics’s complete investors history, request access »

Protexa Therapeutics FAQs

  • When was Protexa Therapeutics founded?

    Protexa Therapeutics was founded in 2008.

  • Where is Protexa Therapeutics headquartered?

    Protexa Therapeutics is headquartered in Duxford, United Kingdom.

  • What industry is Protexa Therapeutics in?

    Protexa Therapeutics’s primary industry is Drug Discovery.

  • Is Protexa Therapeutics a private or public company?

    Protexa Therapeutics is a Private company.

  • What is Protexa Therapeutics’s current revenue?

    The current revenue for Protexa Therapeutics is .

  • Who are Protexa Therapeutics’s investors?

    Total Medical Ventures has invested in Protexa Therapeutics.

  • When was Protexa Therapeutics acquired?

    Protexa Therapeutics was acquired on 01-Jan-2012.

  • Who acquired Protexa Therapeutics?

    Protexa Therapeutics was acquired by E3Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »